« Back
Home /
Zenidolol (hydrochloride)

Zenidolol (hydrochloride)

Item no.	HY-13951-5mg
Manufacturer	MedChem Express
CASRN	72795-01-8
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.74
Citations	[1]Yasuda G, et al. The beta 1- and beta 2-adrenoceptor subtypes in cultured rat inner medullary collecting duct cells. Am J Physiol. 1996 Sep;271(3 Pt 2):F762-9.\|[2]Wenzel D, et al. beta(2)-adrenoceptor antagonist ICI 118,551 decreases pulmonary vascular tone in mice via a G(i/o) protein/nitric oxide-coupled pathway. Hypertension. 2009 Jul;54(1):157-63.\|[3]Gong H, et al. Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart. Circulation. 2002 May 28;105(21):2497-503.\|[4]Hoffmann C, et al. Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Adv Sci (Weinh). 2024 Sep 4:e2402393.\|Biochem Biophys Res Commun. 2024 Feb 15, 149689.\|Biomed Pharmacother. 2023 Mar 15;161:114523.\|bioRxiv. 2020 Jan.\|BMC Ophthalmol. 2021 Dec 5;21(1):419.\|BMC Cancer. 2019 Nov 26;19(1):1142.\|Br J Pharmacol. 2020 Jan;177(2):282-297. \|Cancer Discov. 2024 Aug 13.\|Commun Biol. 2021 Dec 3;4(1):1359.\|Commun Biol. 2022 Apr 8;5(1):339.\|Diabetes. 2022 May 1;71(5):921-933.\|Environ Toxicol. 2023 Dec 2.\|Eur J Pharmacol. 2022 Jun 20;175110.\|Int Dent J. 2024 Jul 22:S0020-6539(24)00166-7.\|Int J Biol Sci. 2023 Apr 2,19.\|J Exp Clin Cancer Res. 2019 Apr 25;38(1):174. \|J Exp Med. 2023 Nov 6;220(11):e20230577.\|J Nutr Biochem. 2018 May 1;58:110-118.\|J Oral Maxillofac Surg. 2020 Oct;78(10):1871.e1-1871.e23.\|J Pharm Anal. 2024 Jan 4.\|Mol Oncol. 2022 May 20.\|Nat Commun. 2020 Sep 25;11(1):4857.\|Nat Commun. 2021 Nov 26;12(1):6937.\|Nat Commun. 2024 Nov 28;15(1):10361.\|Neuroscience. 2019 Mar 1;401:59-72. \|Oncol Rep. 2016 Sep;36(3):1576-84. \|Pflugers Arch. 2021 Sep 26.\|Research Square Preprint. 2020 Oct.\|Research Square Preprint. 2021 Feb.\|Research Square Preprint. 2021 Nov.\|Research Square Preprint. 2021 Sep.\|Research Square Preprint. 2022 Mar.\|Sci Adv. 2024 Jul 19;10(29):eadp5239.\|bioRxiv. 2024 Feb 19.\|J Endocrinol. 2023 Feb 16;256(3):e220335.\|Nat Commun. 2023 May 2;14(1):2523.
Smiles	CC1=C(CCC2)C2=C(OC[C@H](O)[C@@H](C)NC(C)C)C=C1.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ICI-118551 (hydrochloride)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Adrenergic Receptor
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	313.86
Product Description	Zenidolol (ICI-118551) hydrochloride is a highly selective β2 adrenergic receptor antagonist, with Kis of 0.7, 49.5 and 611 nM for β2, β1 and β3 receptors, respectively.
Manufacturer - Research Area	Neurological Disease; Endocrinology
Solubility	DMSO: 25 mg/mL (ultrasonic)\|H2O: 8.33 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein; Neuronal Signaling
Isoform	β adrenergic receptor
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13951-5mg-safety-datasheet.pdf